Scandinavian ChemoTech
1.94 SEK +1.57%Be the first to follow this company
Scandinavian ChemoTech is a research and development company that has developed the technology Tumor-Specific Electroporation - TSE ™ for the treatment of various cancers. The technology means that electronic pulses are sent to the treated area and the membranes of the tumor cells are opened to reach their DNA. In addition to its operations in Sweden, the company is also active in Southeast Asia and India. Scandinavian ChemoTech was founded in 2015 and is headquartered in Lund.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
CMOTEC B
Daily low / high price
1.86 / 2.44
SEK
Market cap
45.29M SEK
Turnover
24.78K SEK
Volume
12K
Financial calendar
Interim report
2024-08-13
Interim report
2024-11-05
Annual report
2025-03-04
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Försäkringsbolaget Avanza | 13.3 % | 11.2 % |
Mohan Frick (privat och genom bolag) | 12.1 % | 20.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Scandinavian ChemoTech's Chief Medical Officer, Suhail Mufti, provides an update on the clinical development and strategy of Medical Affairs
Sista dag för handel med BTA i Scandinavian ChemoTech
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools